Enhanced immune checkpoint inhibitor therapy for advanced recurrent cervical cancer: the key to treatment efficacy and maintenance of quality of life.
作者信息
Kagabu Masahiro, Baba Tsukasa
机构信息
Department of Obstetrics and Gynecology, Iwate Medical University, School of Medicine, Japan.
Department of Obstetrics and Gynecology, Iwate Medical University, School of Medicine, Japan.
出版信息
EBioMedicine. 2024 Oct;108:105386. doi: 10.1016/j.ebiom.2024.105386. Epub 2024 Sep 28.
Abstract
摘要
相似文献
1
Enhanced immune checkpoint inhibitor therapy for advanced recurrent cervical cancer: the key to treatment efficacy and maintenance of quality of life.晚期复发性宫颈癌的强化免疫检查点抑制剂治疗：治疗疗效和维持生活质量的关键。
EBioMedicine. 2024 Oct;108:105386. doi: 10.1016/j.ebiom.2024.105386. Epub 2024 Sep 28.
2
The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study.卡度尼利单抗（PD-1/CTLA-4）与抗PD-1抑制剂在复发性或转移性宫颈癌患者中的疗效和安全性比较：一项回顾性真实世界研究。
Front Immunol. 2025 Jun 2;16:1582299. doi: 10.3389/fimmu.2025.1582299. eCollection 2025.
3
Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer.多西他赛联合卡铂治疗局部晚期或复发性宫颈癌的 II 期临床研究。
Int J Gynecol Cancer. 2010 Dec;20(9):1563-8.
4
Chemotherapy for metastatic and recurrent cervical cancer.转移性和复发性宫颈癌的化疗
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD006469. doi: 10.1002/14651858.CD006469.pub2.
5
Thyroid disorders as predictors of cemiplimab efficacy in recurrent/metastatic cervical cancer: real-world evidence from Poland.甲状腺疾病作为复发/转移性宫颈癌中西米普利单抗疗效的预测指标：来自波兰的真实世界证据
Front Immunol. 2025 Jun 20;16:1604826. doi: 10.3389/fimmu.2025.1604826. eCollection 2025.
6
Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis.免疫检查点抑制剂治疗晚期或复发性子宫内膜癌的疗效和安全性：系统评价和网络荟萃分析。
BMC Cancer. 2024 Oct 21;24(1):1298. doi: 10.1186/s12885-024-13058-z.
7
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.贝伐单抗联合一线拓扑替康-紫杉醇或顺铂-紫杉醇对比不含贝伐单抗的治疗方案用于持续性、复发性或转移性宫颈癌的系统评价和网状荟萃分析
Int J Gynecol Cancer. 2017 Jul;27(6):1237-1246. doi: 10.1097/IGC.0000000000001000.
8
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.比较顺铂和卡铂联合紫杉醇化疗治疗复发性或转移性宫颈癌的系统评价。
Gynecol Oncol. 2014 Apr;133(1):117-23. doi: 10.1016/j.ygyno.2014.01.042. Epub 2014 Jan 31.
9
High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.高剂量率与低剂量率腔内近距离放射治疗局部晚期宫颈癌的比较
Cochrane Database Syst Rev. 2014 Oct 9;2014(10):CD007563. doi: 10.1002/14651858.CD007563.pub3.
10
High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.高剂量率与低剂量率腔内近距离放射治疗局部晚期宫颈癌的比较
Cochrane Database Syst Rev. 2010 Jul 7(7):CD007563. doi: 10.1002/14651858.CD007563.pub2.
本文引用的文献
1
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.西米卢卡法（FAP-IL2v）联合阿替利珠单抗治疗复发性和/或转移性宫颈鳞状细胞癌患者的抗肿瘤活性和安全性的2期研究
EBioMedicine. 2024 Nov;109:105374. doi: 10.1016/j.ebiom.2024.105374. Epub 2024 Oct 11.
2
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.帕博利珠单抗或安慰剂联合放化疗，随后行帕博利珠单抗或安慰剂巩固治疗新诊断的、高危、局部晚期宫颈癌（ENGOT-cx11/GOG-3047/KEYNOTE-A18）：一项随机、双盲、III 期临床研究。
Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20.
3
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.阿替利珠单抗联合贝伐珠单抗和化疗治疗转移性、持续性或复发性宫颈癌（BEATcc）：一项随机、开放标签、3 期临床试验。
Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1.
4
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.度伐利尤单抗联合放化疗对比安慰剂用于局部晚期宫颈癌（CALLA）的随机、双盲、III 期临床试验
Lancet Oncol. 2023 Dec;24(12):1334-1348. doi: 10.1016/S1470-2045(23)00479-5.
5
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.一线帕博利珠单抗+化疗对比安慰剂+化疗用于持续性、复发性或转移性宫颈癌：KEYNOTE-826 的最终总生存结果。
J Clin Oncol. 2023 Dec 20;41(36):5505-5511. doi: 10.1200/JCO.23.00914. Epub 2023 Nov 1.
6
Survival with Cemiplimab in Recurrent Cervical Cancer.西妥昔单抗治疗复发性宫颈癌的生存情况。
N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187.
7
Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.12-13 岁接种二价 HPV 疫苗后 20 岁时的宫颈癌患病率：苏格兰的回顾性人群研究。
BMJ. 2019 Apr 3;365:l1161. doi: 10.1136/bmj.l1161.
Zotero 插件